Value for Patients

Value for patients

Thanks in part to innovative treatments, we can transform diseases such as AIDS and cancer into chronic, well-treatable conditions. Thanks to recent scientific developments, we are also increasingly able to cure people completely or - even better - to prevent them from becoming ill. At Janssen, we continue to work on new treatments that make a difference for patients and society. Our new medical developments should not only extend the lives of patients, but should, above all, improve them. This is why we continue to work towards a future in which disease is a thing of the past.

The improved survival rates for people with serious diseases reflect the progress made in recent decades, thanks in part to pharmaceutical research. For example, the chance of surviving five years after a diagnosis of multiple myeloma (a form of blood cancer also known as "Kahler's disease") has increased significantly. Figures from the Belgian Cancer Registry show that this survival rate after five years increased by 53.8% for men and for women even 60.6% over the period (2014-2018).1 This is partly due to the availability of drugs developed by Janssen.

We consider it equally important to maximize the added value of the care provided. The improved quality of life of the patient is central to this, and it is the patient himself who can best indicate what he or she considers important with regard to the treatment of his or her illness. For this reason, we engage in an ongoing dialogue with them and study, for example, the effects of our treatments with what is called a "Quality of Life" analysis. This analysis draws attention to the impact of the treatment in terms of being able to cope with daily life as best as possible. Factors such as fatigue, nausea, pain perception but also mobility are important here.2  In addition, we are also committed to further improving care on the basis of patients' self-reported experiences. You can read more about this in chapter 8.

+ 20,000

Thanks in part to new medicines and improved treatments, more than 23,000 lives of Belgian HIV patients3 have been saved today that would otherwise have been lost.


In the period from 2012 to 2020, Janssen has introduced 15 new medicines worldwide.

Working on new vaccines

Vaccines are a powerful weapon in the fight against infectious diseases because they prevent people from becoming (seriously) ill in the first place. With the exception of safe drinking water, global vaccination campaigns have had the greatest effect in reducing the global death rate.4  Effective and safe vaccines are also an important tool in stopping the corona pandemic. Therefore, from the moment the genetic code of the coronavirus became known, our research team in Leiden worked relentlessly to develop a COVID-19 vaccine, which we will make available at cost during the corona pandemic.

2-3 million

It is estimated that vaccines can prevent 2 to 3 million deaths per year worldwide.6 


A vaccination program against poliomyelitis resulted in a worldwide reduction of polio cases by 99%.7 


The death rate for cancer has been reduced by 25% since 1991. Innovative cancer drugs - including targeted therapies - have made a significant contribution to this.8 


18 months after the introduction of highly active drug combinations against HIV, hospital spending for people with HIV fell by 43% and total spending on care for people with HIV fell by 16%.9 

Collaborating with patients

To better understand the experiences of patients and learn what is important to them during the entire treatment process, we work closely with various patient organizations. We use the knowledge and experience we gain here in developing and improving our treatments, but also in setting up our clinical studies, for example.

Anneleen Vindevogel

Patient engagement and advocacy manager

Partnering with patients in the R&D process

However, the focus of our partnerships with patients and their relevant organizations goes one step further. By introducing the patient's perspective into every part of our organization, we gain valuable insights that we use to improve the total care around the patient, i.e. also 'beyond the pill'. 

In 2020, we continued our collaboration with a number of patient organizations throughout Belgium, including Ups & Downs vzw, Lymphoma Vereniging Vlaanderen vzw, Psoriasis League vzw and Crohn-RCUH asbl. For the first time we partnered with RaDiOrg, an organization working in the field of rare diseases. These are only a few examples of the partnerships that Janssen currently has.

We are transparent about all our collaborations with patient organizations and we follow the code of conduct of our European professional organization EFPIA.10  This means, for example, that Janssen is never the sole financial sponsor of a project, in order to prevent a patient organization from becoming dependent on one or a limited number of sponsors. There is of course also a code of conduct drawn up by the patient organizations themselves11, which we fully endorse.

Janssen is developing a vaccine against COVID-19

SDG 3: Good health and well-being  





  4. Plotkin, Stanley et al. Plotkin’s vaccines. 7th edition, Elsevier

  5. Global Tuberculosis Report 2020, WHO


  7. World Health Organization

  8. Siegel, Rebecca L. et al (2017). Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians 67, no. 1: 7-30. doi:10.3322/caac.21387

  9. Bozzette, Samuel A. et al (2001). Expenditures for the Care of HIV-Infected Patients in the Era of Highly Active Antiretroviral Therapy. New England Journal of Medicine 344, no. 11: 817-23. doi:10.1056/nejm200103153441107